Literature DB >> 9833853

HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons.

N F Bernard1, K Pederson, F Chung, L Ouellet, M A Wainberg, C M Tsoukas.   

Abstract

BACKGROUND: CD8+ T-cell counts usually increase soon after infection with HIV, whereas CD4+ cell counts decrease. The result of these changes in T-cell subpopulation subsets in most HIV-infected subjects is inversion of the CD4 : CD8 ratio from greater than 1.0 typical of uninfected persons to less than 1.0 after infection.
SUBJECTS: Six HIV-infected individuals were identified in whom the CD4 : CD8 ratio remained normal throughout follow-up (4.0-11.25 years). They all maintained levels of CD4+ cells above 500 x 10(6)/l and had never received antiretroviral therapy. Because HIV-specific cytotoxic T lymphocytes (CTL) have been implicated in control of HIV during the asymptomatic phase of disease, we screened these individuals for the presence of HIV-specific CTL activity.
METHODS: CTL activity was assessed in freshly isolated peripheral blood mononuclear cells (PBMC) and in phytohaemagglutinin-stimulated interleukin-2 expanded cell lines established from PBMC. Cytotoxicity to HIV-1 env, gag, pol and nef gene products was surveyed in a 4 h 51Cr-release assay using autologous Epstein-Barr virus (EBV) transformed B cells infected with vaccinia constructs expressing each of these HIV genes. The immunodominant CTL epitope and MHC class I antigen restriction specificity of HIV-specific CTL was mapped when present. Plasma viral load was assessed by branched DNA assay. Attempts were made to isolate virus from these individuals by the PBMC coculture assay.
RESULTS: None of the six immunologically normal HIV-infected (INHI) subjects exhibited direct HIV-specific CTL activity in their freshly isolated PBMC compared with 16 (47%) out of 34 HIV disease progressors (P = 0.03, chi2 test) and one out of 10 seronegative subjects. Three of the six INHI subjects had detectable memory HIV-specific precursor CTL (pCTL) activity in in vitro-activated T-cell lines compared with 25 (73.5%) out of 34 HIV-1 disease progressors and in none out of 10 seronegative individuals. All three INHI subjects had Gag-specific pCTL, and none had reverse transcriptase-specific pCTL. Plasma HIV viraemia in all six INHI subjects was below the level of detection by branched DNA assay (< 500 copies/ml). Virus could not be isolated from four of these individuals despite multiple attempts to do so by PBMC coculture assays.
CONCLUSION: Direct HIV-specific CTL activity mediated by activated circulating PBMC was undetectable in six INHI individuals under conditions where it is frequently observed in HIV disease progressors. Despite the absence of cells activated for killing HIV-infected targets in the circulation of these individuals, they appeared able to control their HIV infection by maintaining normal levels of CD4 and CD8 cells and low viral load.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833853     DOI: 10.1097/00002030-199816000-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine.

Authors:  Lauren Levitz; Ousmane A Koita; Kotou Sangare; Matthew T Ardito; Christine M Boyle; John Rozehnal; Karamoko Tounkara; Sounkalo M Dao; Youssouf Koné; Zoumana Koty; Soren Buus; Leonard Moise; William D Martin; Anne S De Groot
Journal:  Vaccine       Date:  2012-10-24       Impact factor: 3.641

Review 2.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

3.  Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.

Authors:  Geert Leroux-Roels; Cathy Maes; Frédéric Clement; Frank van Engelenburg; Marieke van den Dobbelsteen; Michael Adler; Mario Amacker; Lucia Lopalco; Morgane Bomsel; Anick Chalifour; Sylvain Fleury
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  Nanotechnology Applications to HIV Vaccines and Microbicides.

Authors:  Sandhya Boyapalle; Subhra Mohapatra; Shyam Mohapatra
Journal:  J Glob Infect Dis       Date:  2012-01

Review 5.  The Antibodiome-Mapping the Humoral Immune Response to HIV.

Authors:  Audrey L Butler; Stephanie Fischinger; Galit Alter
Journal:  Curr HIV/AIDS Rep       Date:  2019-04       Impact factor: 5.071

Review 6.  Innovations in HIV-1 Vaccine Design.

Authors:  Letitia D Jones; M Anthony Moody; Amelia B Thompson
Journal:  Clin Ther       Date:  2020-02-05       Impact factor: 3.393

7.  The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

Authors:  Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.